Technical Articles

In Type 2 immune response-mediated allergic diseases, IL-4Rα serves as the shared subunit of interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, emerging as one of the most sought-after targets in the global biopharmaceutical sector. Through dual inhibition of IL-4/IL-13 signaling pathways, it has not only revolutionized therapeutic paradigms for conventional conditions like atopic dermatitis and asthma but also demonstrated remarkable potential across interdisciplinary fields including tumor immunology and viral infections.